189 related articles for article (PubMed ID: 22149977)
21. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series.
Barreiro-de Acosta M; García-Bosch O; Gordillo J; Mañosa M; Menchén L; Souto R; Marin-Jimenez I;
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):756-8. PubMed ID: 22395225
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for symptom relapse in collagenous colitis after withdrawal of short-term budesonide therapy.
Miehlke S; Hansen JB; Madisch A; Schwarz F; Kuhlisch E; Morgner A; Teglbjaerg PS; Vieth M; Aust D; Bonderup OK
Inflamm Bowel Dis; 2013 Dec; 19(13):2763-7. PubMed ID: 24216688
[TBL] [Abstract][Full Text] [Related]
24. Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients.
Daferera N; Hjortswang H; Ignatova S; Münch A
United European Gastroenterol J; 2019 Nov; 7(9):1234-1240. PubMed ID: 31700636
[TBL] [Abstract][Full Text] [Related]
25. Microscopic colitis: an unfamiliar but treatable disease.
van der Wouden EJ; Karrenbeld A; Kleibeuker JH; Dijkstra G
Neth J Med; 2009 Feb; 67(2):41-5. PubMed ID: 19299845
[TBL] [Abstract][Full Text] [Related]
26. Anorectal function in patients with collagenous colitis in active and clinically quiescent phase, in comparison with healthy controls.
Walter SA; Münch A; Ost A; Ström M
Neurogastroenterol Motil; 2010 May; 22(5):534-8, e118. PubMed ID: 20156310
[TBL] [Abstract][Full Text] [Related]
27. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
[TBL] [Abstract][Full Text] [Related]
28. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
Loftus EV; Feagan BG; Colombel JF; Rubin DT; Wu EQ; Yu AP; Pollack PF; Chao J; Mulani P
Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
30. Budesonide treatment is associated with increased bile acid absorption in collagenous colitis.
Bajor A; Kilander A; Gälman C; Rudling M; Ung KA
Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1643-9. PubMed ID: 17094773
[TBL] [Abstract][Full Text] [Related]
31. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
Gies N; Kroeker KI; Wong K; Fedorak RN
Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
[TBL] [Abstract][Full Text] [Related]
34. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
36. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
37. Lack of effect of methotrexate in budesonide-refractory collagenous colitis.
Münch A; Bohr J; Vigren L; Tysk C; Ström M
Clin Exp Gastroenterol; 2013; 6():149-52. PubMed ID: 24039441
[TBL] [Abstract][Full Text] [Related]
38. [Microscopic colitis--more common cause of diarrhea than believed. Biopsies are the only way to diagnosis, drug treatment is effective].
Tysk C; Bohr J; Olesen M; Eriksson S; Järnerot G
Lakartidningen; 2005 Aug 8-21; 102(32-33):2210-4. PubMed ID: 16145878
[TBL] [Abstract][Full Text] [Related]
39. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
